France's National Agency for Medicines and Health Products Safety fined Novo Nordisk approximately $2 million for misleading advertisements for Wegovy and Saxenda, and fined Eli Lilly roughly $127,000 for Mounjaro advertising that constituted indirect promotion of a prescription-required medicine. The penalties reflect growing regulatory concern over potential misuse of weight loss medications.
French regulator fines
- ▪France's National Agency for Medicines and Health Products Safety fined Eli Lilly roughly $127,000 over advertising for Mounjaro obesity treatment that purportedly amounted to indirect promotion of a medicine for which a prescription is required
- ▪France's National Agency for Medicines and Health Products Safety fined Novo Nordisk approximately $2 million for running misleading advertisements for Wegovy and Saxenda medications
Weight loss drug advertising violations
- ▪Eli Lilly's advertising for Mounjaro obesity treatment purportedly amounted to indirect promotion of a medicine for which a prescription is required
Regulatory scrutiny concerns
- ▪The penalties against Novo Nordisk and Eli Lilly reflect increasing concern among regulators that weight loss medicines may be misused
- ▪Promotions run by pharmaceutical companies for weight loss medicines are being closely scrutinized by regulators
- ▪France's National Agency for Medicines and Health Products Safety issued a bulletin on the risks associated with weight loss drugs in 2024, especially inappropriate use
Perspective of Regulators (France's National Agency for Medicines and Health Products Safety)
- ▪France's National Agency for Medicines and Health Products Safety issued a bulletin on the risks associated with weight loss drugs in 2024, especially inappropriate use
- ▪The penalties against Novo Nordisk and Eli Lilly reflect increasing concern among regulators that weight loss medicines may be misused
Story comments
Loading comments…